AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18406165 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized formulation of IV RhIG (300 microg IM in Study 1; 15 microg/kg IM in Study 2; 50 microg/kg IV in Study 1)
Number of subjects: 142
Study 15944423 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 155
Study 15944423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 12388267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine hydrochloride (5, 10, and 15 microg x kg(‐1) x min(‐1))
Number of subjects: 12
Study 12388267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11116420 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted (LA) colon resection
Number of subjects: 0
Study 11116420 — intervention group
Group type: COMPARATOR
Intervention: Open (O) colon resection
Number of subjects: 0
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 50 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 200 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 50 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 100 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine 200 micrograms
Number of subjects: 48
Study 8638788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 50 micrograms morphine + 50 micrograms neostigmine
Number of subjects: 48
Study 8638788 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 48
Study 1538160 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin with loperamide
Number of subjects: 142
Study 1538160 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day course of 500 mg ciprofloxacin twice daily with loperamide
Number of subjects: 142
Study 1538160 — intervention group
Group type: COMPARATOR
Intervention: 750 mg ciprofloxacin with placebo
Number of subjects: 142
Study 6709544 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) meals (65% carbohydrate)
Number of subjects: 10
Study 6709544 — intervention group
Group type: COMPARATOR
Intervention: High Fat (HF) meals (12% carbohydrate, 71% fat)
Number of subjects: 10
Study 30079814 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 217
Study 30079814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 28990434 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES combined with strengthening exercise
Number of subjects: 100
Study 28990434 — intervention group
Group type: COMPARATOR
Intervention: Only NMES
Number of subjects: 100
Study 26433546 — intervention group
Group type: EXPERIMENTAL
Intervention: Xilonix plus standard of care
Number of subjects: 43
Study 23295313 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐mo moderate‐intensity physical activity (PA)
Number of subjects: 424
Study 23295313 — intervention group
Group type: COMPARATOR
Intervention: Successful aging (SA) health education intervention
Number of subjects: 424
Study 23018219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 5 or 10 mg daily for 13 weeks
Number of subjects: 546
Study 23018219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 546
Study 23018219 — intervention group
Group type: COMPARATOR
Intervention: Placebo or gonadotropin-releasing hormone agonist
Number of subjects: 546
Study 19101921 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending service with a Befriender Facilitator (BF) and trained lay volunteer befriender
Number of subjects: 236
Study 19101921 — intervention group
Group type: COMPARATOR
Intervention: No BF contact (Control)
Number of subjects: 236
Study 19101921 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending service
Number of subjects: 236
Study 17205530 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs (prescription for at least 1 year)
Number of subjects: 10336
Study 17205530 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (prescription for at least 1 year)
Number of subjects: 10336
Study 17205530 — intervention group
Group type: COMPARATOR
Intervention: No prescription of non-aspirin NSAIDs
Number of subjects: 10336
Study 16115963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 132
Study 16115963 — intervention group
Group type: COMPARATOR
Intervention: 3% modified fluid gelatin (GEL)
Number of subjects: 132
Study 11840236 — intervention group
Group type: EXPERIMENTAL
Intervention: BiliCheck system (multiple wavelength analysis of reflectance data)
Number of subjects: 101
Study 11840236 — intervention group
Group type: COMPARATOR
Intervention: Jaundice Meter JM‐102 (two‐wavelength bilirubinometer)
Number of subjects: 101
Study 10068848 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprindine (60 mg daily)
Number of subjects: 38
Study 7627485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunar dual-energy X-ray absorptiometry scanner
Number of subjects: 12
Study 7627485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hologic dual-energy X-ray absorptiometry scanner
Number of subjects: 12
Study 7627485 — intervention group
Group type: EXPERIMENTAL
Intervention: Norland dual-energy X-ray absorptiometry scanner
Number of subjects: 12
Study 7627485 — intervention group
Group type: COMPARATOR
Intervention: Measurements from phantoms
Number of subjects: 12
Study 7627485 — intervention group
Group type: COMPARATOR
Intervention: European Spine Phantom
Number of subjects: 12
Study 1903497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg b.i.d. (increased to 40 mg per day after 8 weeks)
Number of subjects: 45
Study 1903497 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine 8 g b.i.d. (added after 16 weeks)
Number of subjects: 45
Study 1903497 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrocil 900 mg (two thirds of cholestyramine group switched)
Number of subjects: 45
Study 7342466 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyloestrenol (Gestanon) 10 mg daily until the 8th week, then 15 to 20 mg daily until the 12th week, then tapered off
Number of subjects: 198
Study 7342466 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyloestrenol (Gestanon) administered immediately after ovulation
Number of subjects: 198
Study 7342466 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyloestrenol (Gestanon) administered after the first missed period
Number of subjects: 198
Study 29869444 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL-assisted MAL-PDT with 1-h incubation
Number of subjects: 42
Study 29869444 — intervention group
Group type: COMPARATOR
Intervention: Conventional MAL-PDT (CPDT)
Number of subjects: 42
Study 30149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Genipap juice
Number of subjects: 16
Study 25881805 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention program
Number of subjects: 8
Study 24501379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling intervention
Number of subjects: 632
Study 24501379 — intervention group
Group type: COMPARATOR
Intervention: Mailed packet with general information about screening
Number of subjects: 632
Study 22714067 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular aspiration + flushing
Number of subjects: 200
Study 22714067 — intervention group
Group type: COMPARATOR
Intervention: Follicular aspiration only
Number of subjects: 200
Study 19576120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg, 3/d)
Number of subjects: 237
Study 19576120 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (100 mg, 3/d)
Number of subjects: 237
Study 17895886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5‐fluorouracil (5‐FU) and leucovorin (LV)
Number of subjects: 500
Study 17895886 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only
Number of subjects: 500
Study 17895886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5‐FU and LV
Number of subjects: 500
Study 15648443 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-like peptide gel (3% collagen-like peptide and 1% booster molecule)
Number of subjects: 20
Study 15648443 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 11164130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E intake from supplements
Number of subjects: 1047
Study 11164130 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1047
Study 11164130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary factors (including serum retinol, carotenoids, supplemental vitamin C, alpha-tocopherol intake from food, dietary fiber, and Hispanic ethnicity)
Number of subjects: 1047
Study 11164130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol intake from food, total fat intake, and BMI
Number of subjects: 1047
Study 11164130 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, income, hormone use, and geographic location
Number of subjects: 1047
Study 9581724 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg twice daily) for 6 months
Number of subjects: 98
Study 9581724 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 98
Study 8043664 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) insulin administration
Number of subjects: 6
Study 8043664 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal (IP) insulin administration
Number of subjects: 6
Study 2927479 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (resuscitation with intravenous fluids, nasogastric suction, intravenous antibiotics including cefuroxime, ampicillin, metronidazole, and ranitidine)
Number of subjects: 83
Study 2927479 — intervention group
Group type: COMPARATOR
Intervention: Immediate laparotomy and repair of the perforation
Number of subjects: 83
Study 2927479 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 83
Study 48727 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent glycerol for 6 days
Number of subjects: 61
Study 48727 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (16 mg. per 24 hours for 6 days)
Number of subjects: 61
Study 30102685 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 16
Study 30102685 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 16
Study 31094443 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 month aerobic exercise program
Number of subjects: 175
Study 31094443 — intervention group
Group type: COMPARATOR
Intervention: Sedentary after-school program
Number of subjects: 175
Study 28878472 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal contraction exercise of the rectus abdominis during isometric contraction of the transversus abdominis
Number of subjects: 30
Study 28878472 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 25208848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest screening before CIT
Number of subjects: 152
Study 23759410 — intervention group
Group type: EXPERIMENTAL
Intervention: Website only (W)
Number of subjects: 101
Study 23759410 — intervention group
Group type: EXPERIMENTAL
Intervention: Website, monthly group sessions, and follow-up calls (WG)
Number of subjects: 101
Study 23759410 — intervention group
Group type: EXPERIMENTAL
Intervention: Website and SMS (WSMS)
Number of subjects: 101
Study 23759410 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 101
Study 21486975 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing schedule (0, 2, and 6 months)
Number of subjects: 903
Study 21486975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative dosing schedule (0, 3, and 9 months)
Number of subjects: 903
Study 21486975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative dosing schedule (0, 6, and 12 months)
Number of subjects: 903
Study 21486975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative dosing schedule (0, 12, and 24 months)
Number of subjects: 903
Study 18277020 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 4.5 microg bid
Number of subjects: 36
Study 18277020 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 9 microg bid
Number of subjects: 36
Study 18277020 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 18 microg bid
Number of subjects: 36
Study 18277020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 18277020 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol (all dosages)
Number of subjects: 36
Study 18277020 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol (higher dosages)
Number of subjects: 36
Study 16485186 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RF ablation)
Number of subjects: 46
Study 16485186 — intervention group
Group type: EXPERIMENTAL
Intervention: RF ablation combined with left atrial size reduction
Number of subjects: 46
Study 12588635 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis extract
Number of subjects: 46
Study 12588635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 10955199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere, 0.1%
Number of subjects: 35
Study 10955199 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin cream, 0.025%
Number of subjects: 35
Study 9709370 — intervention group
Group type: EXPERIMENTAL
Intervention: Short tubing/port (STP) setup with gravity flow
Number of subjects: 10
Study 9709370 — intervention group
Group type: EXPERIMENTAL
Intervention: Short tubing/port (STP) setup with manual pressure
Number of subjects: 10
Study 9709370 — intervention group
Group type: EXPERIMENTAL
Intervention: Short tubing/port (STP) setup with pneumatic pressure at 300 mm Hg
Number of subjects: 10
Study 9709370 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) setup with gravity flow
Number of subjects: 10
Study 9709370 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) setup with manual pressure
Number of subjects: 10
Study 9709370 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CON) setup with pneumatic pressure at 300 mm Hg
Number of subjects: 10
Study 8150763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 h
Number of subjects: 231
Study 8150763 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g every 8 h
Number of subjects: 231
Study 3620277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg once daily
Number of subjects: 479
Study 3620277 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 479
Study 29718782 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS program (peer‐led group intervention)
Number of subjects: 28
Study 28685553 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and epirubicin
Number of subjects: 218
Study 28685553 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin
Number of subjects: 218
Study 26216331 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB, PCV13, and RV5
Number of subjects: 1465
Study 26216331 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB
Number of subjects: 1465
Study 26216331 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited adverse events in group 1
Number of subjects: 1465
Study 26216331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever in group 1
Number of subjects: 1465
Study 23022285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - pioglitazone and rosiglitazone
Number of subjects: 2
Study 23022285 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month pioglitazone treatment
Number of subjects: 2
Study 23022285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 20338054 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study 20338054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18922508 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP intervention
Number of subjects: 0
Study 18922508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16292592 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg nocturnally administered for 15 days
Number of subjects: 6
Study 16292592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15061398 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Cetirizine (M-C group)
Number of subjects: 30
Study 15061398 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast + Desloratadine (M-D group)
Number of subjects: 30
Study 10770189 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.1 IU/kg day)
Number of subjects: 99
Study 10770189 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.2 IU/kg day)
Number of subjects: 99
Study 10770189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9413087 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell rabies vaccine
Number of subjects: 72
Study 9413087 — intervention group
Group type: COMPARATOR
Intervention: Human diploid cell rabies vaccine and human rabies immune globulin
Number of subjects: 72
Study 9413087 — intervention group
Group type: EXPERIMENTAL
Intervention: Chick embryo vaccine without immune globulin
Number of subjects: 72
Study 9413087 — intervention group
Group type: EXPERIMENTAL
Intervention: Chick embryo rabies vaccine with immune globulin
Number of subjects: 72
Study 8405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 2.0 mg micronized 17 beta‐oestradiol
Number of subjects: 9
Study 8405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 0.500 mg 17 beta‐oestradiol cyclo‐octyl acetate
Number of subjects: 9
Study 8405014 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mg desogestrel + 1.0 mg 17 beta‐oestradiol decanoate
Number of subjects: 9
Study 2939221 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous ketanserin (0.15 mg/kg)
Number of subjects: 10
Study 2939221 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral ketanserin (40 mg)
Number of subjects: 10
Study 2939221 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral ketanserin (40 mg once-daily)
Number of subjects: 10
Study 30760444 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device
Number of subjects: 0
Study 30760444 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 0
Study 29940055 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot adductor canal block (SS-ACB) with 20 mL of 0.5% ropivacaine preoperatively and saline boluses at 12 and 24 hours postoperatively
Number of subjects: 75
Study 29940055 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (C-ACB) with 20 mL of 0.5% ropivacaine preoperatively and at 12 and 24 hours postoperatively
Number of subjects: 75
Study 29940055 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving saline preoperatively and postoperatively
Number of subjects: 75
Study 27145958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean calorie‐restricted diet (n = 50)
Number of subjects: 100
Study 27145958 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian calorie‐restricted diet (n = 50)
Number of subjects: 100
Study 24114435 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E₂) supplementation
Number of subjects: 24
Study 24114435 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E₂) concentrations
Number of subjects: 24
Study 24114435 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 24
Study 24114435 — intervention group
Group type: EXPERIMENTAL
Intervention: E₂ and BMI
Number of subjects: 24
Study 22950868 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescripted Image repetition
Number of subjects: 55
Study 22950868 — intervention group
Group type: COMPARATOR
Intervention: Index Image repetition
Number of subjects: 55
Study 20485221 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional balance training
Number of subjects: 35
Study 20485221 — intervention group
Group type: COMPARATOR
Intervention: Computer feedback balance training
Number of subjects: 35
Study 20485221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (both interventions)
Number of subjects: 35
Study 18554755 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-helminthic therapy
Number of subjects: 0
Study 18554755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18554755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (upon stimulation with Con A)
Number of subjects: 0
Study 11683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine
Number of subjects: 0
Study 11683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0
Study 11683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine/ASA combination
Number of subjects: 0
Study 11683039 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 11683039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine (10 nM) in vitro
Number of subjects: 0
Study 9471022 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha at a dosage of 2‐4 mega units/square metre of body surface area thrice weekly for 6‐12 months
Number of subjects: 142
Study 9471022 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosage and longer treatment duration of IFN‐alpha for patients infected with HCV genotype 1b
Number of subjects: 142
Study 7525125 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 150 mg daily
Number of subjects: 23
Study 3598162 — intervention group
Group type: COMPARATOR
Intervention: lactulose (30 ml/6 h)
Number of subjects: 40